ArticleScientific reports2025
A machine learning based prediction model for short term efficacy of nasopharyngeal carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The radiological dosimetric parameters and clinical features were screened by machine learning to construct a prediction model for the short-term efficacy of locally advanced Nasopharyngeal Carcinoma (LANPC). Patients diagnosed with Nasopharyngeal Carcinoma were retrospectively collected in the study. Twenty-four clinical features and twelve radiological dosimetric features were included. Three machine learning algorithms were used to construct predictive models for the short-term efficacy of LANPC. Kaplan-Meier log-rank method was used to compare the prognosis of patients with different efficacies in the model. The reliability of the model was evaluated using the calibration curve and the area under the curve (AUC). There were 194 patients who met the inclusion criteria. Among the three models being constructed, Random forest (RSF) model showed the best predictive ability, with AUC values of 1.000 in the training group and 0.944 in the test group, followed by XGBoost decision tree (GBDT) model (0.866/0.849) and decision tree (DT) model (0.848/0.783). In RSF model, the 3-year and 5-year overall survival rates of patients in complete remission (CR) group were 98.9% (95% CI 0.9688-1.0000) and 89.7% (95% CI 0.8256-0.9752), respectively.While for patients in non-CR group, the 3-year and 5-year overall survival (OS) rate was 100% (95%CI 1.000~1.000) and 98.8% (95% CI 0.9652-1.0000), respectively. There has statistically significant difference between the two groups (P = 0.0037). RSF model constructed by machine-learning algorithm based on radiological dosimetric parameters and clinical characteristics can better predict the short-term efficacy of LANPC, and is an effective tool to evaluate the short-term efficacy of different LANPC patients during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.